Last reviewed · How we verify
NCT03732846
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
Status unknown
Phase 2
Last updated 7 November 2018
What this trial tests
Phase 2 trial testing Anlotinib in Recurrent Small Cell Lung Cancer in 43 participants. Status unknown.
Timeline
1 November 2018
Primary endpoint
1 May 2020
1 May 2020
1 May 2020
Quick facts
| Lead sponsor | Peking University Cancer Hospital & Institute |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 1 November 2018 |
| Primary completion | 1 May 2020 |
| Estimated completion | 1 May 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anlotinib — full drug profile →
Conditions studied
- Recurrent Small Cell Lung Cancer — all drugs for Recurrent Small Cell Lung Cancer →
Sponsor
Peking University Cancer Hospital & Institute
Who can join
18 and older, any sex, with Recurrent Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
Wu D, Nie J, Hu W, Dai L, et al · · 2020 · cited 30× · PMID 32557583 · DOI 10.1002/ijc.33161 -
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies.
Cani M, Napoli VM, Garbo E, Ferrari G, et al · · 2023 · cited 11× · PMID 37240229 · DOI 10.3390/ijms24108883 -
Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.
Wang W, Wu G, Luo W, Lin L, et al · · 2024 · cited 4× · PMID 39333988 · DOI 10.1186/s12885-024-12954-8 -
Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future.
Wakuda K. · · 2020 · cited 1× · PMID 32420056 · DOI 10.21037/tlcr.2020.03.10 -
Application and mechanistic research of novel therapeutic strategies in cisplatin-resistant small cell lung cancer.
Chen Z, Qiang M, Dong J, Gong K, et al · · 2026 · PMID 41869709 · DOI 10.1080/07853890.2025.2601401
Verify or expand the search:
- PubMed search for NCT03732846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anlotinib
Trials testing the same drug.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
- NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
- NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting
Other recruiting trials for Recurrent Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06681220 — Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC · Phase 1, PHASE2 · recruiting
Other Peking University Cancer Hospital & Institute trials
Trials by the same sponsor.
- NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
- NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
- NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03732846 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
- Last refreshed: 7 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03732846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing